Breathing new life into in vivo lung editing
New lipid nanoparticle designs make targeted in vivo lung editing possible in mice and may lead to new treatment options for cystic fibrosis.
原文链接 https://www.nature.com/articles/s41587-024-02338-5 News
1. CAR-Ts sweep into autoimmunityBiotechs are equipping CAR-T cells to destroy B cells — not to treat blood cancers, but to take on multiple sclerosis and a raft of autoimmune disorders.原文链接 https://www.nature.com/articles/s41587-024-02321-0 Neurons in multiple sclerosis are damaged by autoantibodies and inflammation. Credit: Stocktrek Images, Inc. / Alamy Stock Photo2. Fungal detox: investors eye mycelium bioremediation
The digestive prowess of fungi to decontaminate natural environments from polluting plastics, oil spills, toxic waste and even radiation is gaining traction around the globe.原文链接 https://www.nature.com/articles/s41587-024-02315-y Fungal mycelia branch out underground. Environmental and Indigenous groups have used mycelia with success for soil and water remediation. Credit: Justin Long / Alamy Stock Photo1. Roche bets on RNA exon editor原文链接 https://www.nature.com/articles/s41587-024-02329-6 2. Bezos backs taste-good lab proteins原文链接 https://www.nature.com/articles/s41587-024-02330-z 原文链接 https://www.nature.com/articles/s41587-024-02333-w 4. Biotech news from around the world原文链接 https://www.nature.com/articles/s41587-024-02328-7 1. Precision radiation opens a new window on cancer therapy
Targeted radiopharmaceuticals offer resistance-free potency, pre-treatment imaging and widespread combination potential. Big pharma and investors are piling in.
原文链接 https://www.nature.com/articles/s41587-024-02295-z ImagesRouges / Alamy Stock Photo2. Editor’s pick: Tome BiosciencesEach year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Tome Biosciences inserts large DNA sequences into precise genomic locations, overcoming limitations of base and prime editing.原文链接 https://www.nature.com/articles/s41587-024-02280-6Jonathan Gootenberg (left) and Omar Abudayyeh. Credit: Tome Biosciences
3. Editor’s pick: Tenpoint Therapeutics
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Tenpoint Therapeutics optimizes delivery and generation of stem-cell-derived retinal cells for vision repair.原文链接 https://www.nature.com/articles/s41587-024-02281-5 Peter Coffey Credit: Tenpoint Therapeutics1. The cost of drug patent expiration date errorsErrors in the US Patent and Trademark Office’s automated program to calculate patent expiration dates could result in hundreds of millions of dollars in added costs to drug prices.原文链接 https://www.nature.com/articles/s41587-024-02298-w
2. Super-resolution microscopyRecent patents relating to systems and methods for super-resolution microscopy.
原文链接 https://www.nature.com/articles/s41587-024-02304-1
版权声明：中文内容仅供参考，一切内容以英文原版为准，欢迎转发至朋友圈。未经允许，请勿转载。未经授权的翻译是侵权行为，版权方将保留追究法律责任的权利。
© 2024 Springer Nature Limited. All Rights Reserved.
